Acute Kidney Injury Market: Epidemiology, Therapies, Companies, DelveInsight | Atox Bio, AM-Pharma Holding, Quark-Pharmaceuticals, LG Chem, Pharming Group, Angion Biomedica, Elysium Health, Sentien Biotechnologies, Pharmazz, Arch Biopartners, Guard Therap

Acute Kidney Injury therapies, such as RBT-1, OCE-205, and others, are expected to boost the Acute Kidney Injury Market in the upcoming years.

DelveInsight has launched a new report on "Acute Kidney Injury - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Acute Kidney Injury, historical and forecasted epidemiology as well as the Acute Kidney Injury market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover about the Acute Kidney Injury market report @ https://www.delveinsight.com/report-store/acute-kidney-injury-aki-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Some of the key facts of the Acute Kidney Injury Market Report:

Currently, no targeted pharmacological treatments have been approved specifically for Acute Kidney Injury. The therapeutic landscape is largely dominated by renal replacement therapy (RRT) and off-label use of drugs such as ACE inhibitors, ARBs, diuretics, and NSAIDs.
The incidence of AKI continues to rise, especially among patients with acute medical conditions or those undergoing major surgeries.
In 2022, there were approximately 14.6 million mortality-adjusted incident cases of AKI among hospitalized patients across the 7MM. That year, the U.S. represented the largest share of AKI incident cases among the seven major markets (7MM), contributing approximately 39% of the total.
The United States represented the largest share of the AKI market in 2022, accounting for around 65% of the total market size in the 7MM. This share is projected to grow further by 2034.
In June 2024, SeaStar Medical achieved an interim enrollment milestone in its pivotal NEUTRALIZE-AKI adult trial for the Selective Cytopheretic Device (SCD). A Data Safety Monitoring Board (DSMB) review is expected in mid-2025.
In December 2023, SeaStar Medical began enrolling patients for the NEUTRALIZE-AKI clinical trial evaluating its cell-targeted Selective Cytopheretic Device (SCD) in critically ill adults with AKI requiring continuous kidney replacement therapy (CKRT).
In October 2023, Renibus Therapeutics dosed the first patient in its pivotal Phase III PROTECT trial for RBT-1, aimed at managing post-operative complications following cardiac surgery. Top-line data are expected by mid-2025, with an NDA submission planned for early 2026.
Key Acute Kidney Injury companies such as Atox Bio, AM-Pharma Holding, Quark-Pharmaceuticals, LG Chem, Pharming Group, Angion Biomedica, Elysium Health, Sentien Biotechnologies, Pharmazz, Arch Biopartners, Guard Therapeutics, RegeneRx Biopharmaceuticals, Cerenis Therapeutics, Alloksys, Vifor Pharma, and others are evaluating new drugs for Acute Kidney Injury to improve the treatment landscape.
Promising Acute Kidney Injury therapies include RBT-1, OCE-205, and others.

Acute Kidney Injury Overview

Acute Kidney Injury (AKI) is typically characterized by a sudden decline in kidney function, which is clinically indicated by a temporary rise in nitrogenous waste products, such as blood urea nitrogen (BUN) and serum creatinine, occurring over a period of hours to weeks.

Common symptoms of AKI include nausea, vomiting, fatigue, dizziness, and lower back pain. However, some individuals may not exhibit any noticeable symptoms, while others may experience general, non-specific signs that are not directly linked to kidney function.

Acute Kidney Injury Market Insights

Patients with Acute Kidney Injury are frequently treated with diuretics, with loop diuretics being the most commonly prescribed type. Among these, furosemide is widely used across various stages of AKI due to its strong efficacy in promoting the excretion of significant amounts of water and electrolytes, provided the kidneys retain some filtering capacity.

Acute Kidney Injury Market Outlook

The Acute Kidney Injury therapeutics market is being driven by a growing pipeline of drugs with novel mechanisms of action and a rising incidence of the condition. This evolving pipeline is expected to reshape the current treatment landscape, which is currently dominated by renal replacement therapy (RRT) and off-label use of medications such as ACE inhibitors, ARBs, diuretics, and NSAIDs. Notably, there are still no approved targeted pharmacotherapies specifically for AKI treatment.

The presence of comorbid conditions like cardiovascular disease, hypertension, diabetes, chronic kidney disease (CKD), and impaired renal recovery further elevates the risk of developing AKI. Although traditional treatment approaches still dominate, the future of the AKI market is likely to change, driven by new therapies in development that focus on AKI resulting from complications such as sepsis, cardiac surgery, and delayed graft function.

Emerging pipeline candidates are addressing specific subtypes of AKI, including hepatorenal syndrome-associated AKI (HRS-AKI), sepsis-induced AKI, and AKI following cardiac procedures. These innovative therapies have the potential to significantly reduce the existing unmet needs in AKI treatment.

Key players advancing novel AKI treatments include Renibus Therapeutics (RBT-1), Ocelot Bio (OCE-205), AM-Pharma (Ilofotase alfa), and Guard Therapeutics (RMC-035), among others. These companies are focused on developing therapies aimed at improving outcomes and lowering mortality rates in hospitalized patients. Overall, the AKI therapeutics market is projected to expand steadily throughout the forecast period from 2024 to 2034.

Discover how the Acute Kidney Injury market is rising in the coming years @ https://www.delveinsight.com/sample-request/acute-kidney-injury-aki-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Acute Kidney Injury Emerging Drugs
RBT-1: Renibus Therapeutics
OCE-205: Ocelot Bio

Scope of the Acute Kidney Injury Market Report
Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Acute Kidney Injury Companies: Atox Bio, AM-Pharma Holding, Quark-Pharmaceuticals, LG Chem, Pharming Group, Angion Biomedica, Elysium Health, Sentien Biotechnologies, Pharmazz, Arch Biopartners, Guard Therapeutics, RegeneRx Biopharmaceuticals, Cerenis Therapeutics Alloksys, Vifor Pharma, and others
Acute Kidney Injury Therapies: RBT-1, OCE-205, and others.
Acute Kidney Injury Therapeutic Assessment: Acute Kidney Injury current marketed and Acute Kidney Injury emerging therapies
Acute Kidney Injury Market Dynamics: Acute Kidney Injury market drivers and Acute Kidney Injury market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Acute Kidney Injury Unmet Needs, KOL's views, Analyst's views, Acute Kidney Injury Market Access and Reimbursement

To know what's more in our Acute Kidney Injury report, visit https://www.delveinsight.com/report-store/acute-kidney-injury-aki-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key benefits of the Acute Kidney Injury Market Report:
The Acute Kidney Injury market report covers a descriptive overview and comprehensive insight of the Acute Kidney Injury Epidemiology and Acute Kidney Injury market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).
The Acute Kidney Injury market report provides insights into the current and emerging therapies.
The Acute Kidney Injury market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Acute Kidney Injury market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Acute Kidney Injury market.

Got queries? Click here to know more about the Acute Kidney Injury market Landscape https://www.delveinsight.com/sample-request/acute-kidney-injury-aki-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Contents

1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Acute Kidney Injury Patient Share (%) Overview at a Glance
5. Acute Kidney Injury Market Overview at a Glance
6. Acute Kidney Injury Disease Background and Overview
7. Acute Kidney Injury Epidemiology and Patient Population
8. Country-Specific Patient Population of Acute Kidney Injury
9. Acute Kidney Injury Current Treatment and Medical Practices
10. Unmet Needs
11. Acute Kidney Injury Emerging Therapies
12. Acute Kidney Injury Market Outlook
13. Country-Wise Acute Kidney Injury Market Analysis (2020-2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Acute Kidney Injury Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Click here to read more about Acute Kidney Injury Market Outlook 2034 https://www.delveinsight.com/report-store/acute-kidney-injury-aki-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Related Reports:

Acute Kidney Injury Pipeline Insights, DelveInsight

"Acute Kidney Injury Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Acute Kidney Injury market. A detailed picture of the Acute Kidney Injury pipeline landscape is provided, which includes the disease overview and Acute Kidney Injury treatment guidelines.

Contact Info:

Kritika Rehani, Assistant Manager, Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
www.delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.